High-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Ménière’s disease: a case series

Franziska Lezius • Christine Adrion •
Ulrich Mansmann • Klaus Jahn • Michael Strupp

 

The objective of this study was to evaluate the
clinical benefit and the side effects of high dosages of
betahistine dihydrochloride (288–480 mg/day) in patients
with severe Ménière’s disease (MD).

 

Clicca qui per aprire l’articolo

0 commenti

Lascia un Commento

Vuoi partecipare alla discussione?
Fornisci il tuo contributo!

Lascia un commento

Il tuo indirizzo email non sarà pubblicato. I campi obbligatori sono contrassegnati *